GSK pulls ahead of Pfizer in RSV vaccine market as Arexvy nears blockbuster status
Pfizer cans twice-daily oral obesity program
3 medtech spinoffs that reshaped the industry in 2023
FDA starts review of Padcev/Keytruda for bladder cancer
*please scroll down for all the latest news*